Market News & Trends
Gattefossé Strengthens its CSR Approach & Reaches Two Major Milestones
In line with its CSR commitment, Gattefossé has received ISO 14001:2015 certification for its main production site in France and has been ranked in the…
Biomerica Announces Positive Topline Results From the Endpoint Clinical Trial
Biomerica, Inc. recently announced positive topline results from the endpoint clinical trial of its InFoods IBS diagnostic-guided therapy (DGT), with the trial showing statistically significant…
Eyenovia Concludes Type A Meeting With FDA Related to MydCombi NDA Resubmission
Eyenovia, Inc. recently announced that the company successfully completed a Type A meeting with the US FDA related to the refiling of the NDA for…
Recce Pharmaceuticals Announces Positive Safety Data From Third Cohort of Phase 1 Clinical Trial
Recce Pharmaceuticals Ltd recently reported Phase 1 intravenous (IV) clinical trial of RECCE 327 (R327) cohort three at 500mg (tenfold increase on cohort one 50mg…
Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 & MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells
Kintara Therapeutics, Inc. recently announced the US PTO has issued to Kintara United States Patent No. 11,234,955 covering a method of treating brain tumors including…
POP Biotechnologies Vaccine Technology to Enter Phase 3 Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19
POP Biotechnologies recently announced the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean…
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial
Evelo Biosciences, Inc. recently announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate…
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
uniQure N.V. recently announced the dosing of the first two patients in its European open-label Phase 1b/2 clinical trial of AMT-130, a potential one-time gene-therapy…
Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the US & Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Immunic, Inc. recently announced the company received a Notice of Allowance from the USPTO for patent application 16/644581 titled IL-17 and IFN-gamma inhibition for the…
ImCheck Announces First Patients Dosed in Phase 2 of EVICTION Trial for ICT01
ImCheck Therapeutics recently announced the first patients have been dosed in the Phase 2a monotherapy expansion arm in the ongoing Phase 1/2a EVICTION clinical trial…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….